Market Place
Sourcing Support
JAMA Study Shows Income Disparities In Type 2 Diabetes Outcomes
12 Dec 2024 //
BUSINESSWIRE
TheracosBio, PBA Partner For Affordable Diabetes Drug Access
03 Oct 2024 //
BUSINESSWIRE
BRENZAVVY Remains Lowest Priced SGLT2 Inhibitor Post IRA
28 Aug 2024 //
BUSINESSWIRE
IPC Secures Distribution Rights to Independent Retail Pharmacies for BRENZAVVY
01 Feb 2024 //
PR NEWSWIRE
CV Safety Profile of TheracosBio’s BRENZAVVY Confirmed in Research Published
08 Jan 2024 //
BUSINESSWIRE
TheracosBio, IPC Announce Partnership to Make BRENZAVVY Available
20 Dec 2023 //
BUSINESSWIRE
TheracosBio and SmithRx Collaborate to Offer Approved Diabetes Drug Brenzavvy
17 Aug 2023 //
BUSINESSWIRE
TheracosBio Announces Publication of Data on the Safety of Brenzavvy
04 Aug 2023 //
BUSINESSWIRE
TheracosBio Announces Commercial Availability of Brenzavvy
13 Jul 2023 //
BUSINESSWIRE
Piramal Supports Theracosbio With Integrated Drug Substance Program For Bexagliflozin
30 Mar 2023 //
PR NEWSWIRE
TheracosBio wins FDA green light for new diabetes med
24 Jan 2023 //
FIERCE PHARMA
Elanco Announces FDA Approval of Bexacat (bexagliflozin tablets)
09 Dec 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.